Here’s why Ozempic maker’s new weight-loss drug isn’t good enough for investors

New trial data showed CagriSema led to “superior” weight loss, but at a rate much less than original expectations of 25%.

Topics

Novo Nordisk shares fall 6.3% after latest trial results for its next-generation weight loss drug

Shares of Novo Nordisk fell sharply on Monday, after the firm published results from the latest clinical trial of its CagriSema weight-loss drug.
CNBC - 3h
Chipmakers are finding that good earnings aren't enough to please Wall Street

After investors poured into semiconductor stocks last year, expectations are high, and companies are having trouble making Wall Street happy.
CNBC - 2d
These accounts can be the 'worst possible asset’ for retirement, expert says. Here's why

Many investors don't plan for future taxes when contributing to traditional IRAs. Here are the key things to know.
CNBC - 2d
Weight Loss Drug Will Be Offered for $499 a Month for Some Patients

Some commercially insured patients stand to save $150 per month on Wegovy, a popular obesity medication. Patients on Medicare and Medicaid are not eligible.
The New York Times - 4d
Best 7 Coffee Makers (2025): Drip Is Drippin'

The old-fashioned drip coffee maker has come a long way. Our favorite machines here can turn your barista into a stranger.
Wired - 3d
Death of a Unicorn review – goofy eat-the-rich satire isn’t fun enough

SXSW film festival: Jenna Ortega, Paul Rudd and Richard E Grant lead a wasted cast in this silly and exasperating mishmash of comedy and gore. The unicorn has been a staple of folk mythology for ...
The Guardian - 23h
Hikma races to launch generic versions of blockbuster obesity drugs

Pharma group looks to take advantage as Wegovy and Ozempic start to go off patent next year
Financial Times - 1d
The M3 iPad Air Is Unsurprisingly Good

The iPad Air with M3 isn’t much different, but that shouldn’t surprise you.
Inc. - 2h
More couples are choosing lab-grown diamonds over natural stones for engagement rings. Here’s why

Lab-grown diamonds outpace natural stones when it comes to engagement rings. Here’s why, and what to consider when shopping.
CNBC - 3h

Here’s why Ozempic maker’s new weight-loss drug isn’t good enough for investors

Topics

Related

Novo Nordisk shares fall 6.3% after latest trial results for its next-generation weight loss drug

Chipmakers are finding that good earnings aren't enough to please Wall Street

These accounts can be the 'worst possible asset’ for retirement, expert says. Here's why

Weight Loss Drug Will Be Offered for $499 a Month for Some Patients

Best 7 Coffee Makers (2025): Drip Is Drippin'

Death of a Unicorn review – goofy eat-the-rich satire isn’t fun enough

Hikma races to launch generic versions of blockbuster obesity drugs

The M3 iPad Air Is Unsurprisingly Good

More couples are choosing lab-grown diamonds over natural stones for engagement rings. Here’s why

More from MarketWatch

LinkedIn co-founder has known Elon Musk for years. Here’s what he says Americans don’t understand about the Tesla CEO.

Redfin’s stock soars on buyout deal with Rocket Cos. that looks to speed up home buying

Do older adults understand healthcare risks?

These 13 growth stocks are expected to roar back from their declines so far this year

Treasury yields tumble as stocks skid on tariff concerns, U.S. recession talk

More in Business

Volkswagen and Stellantis evade Trump's 25% tariffs, while BMW braces for impact

Here's why Home Depot is outperforming — and Jim Cramer's advice on the stock

Lila Sciences Uses A.I. to Turbocharge Scientific Discovery

LinkedIn co-founder has known Elon Musk for years. Here’s what he says Americans don’t understand about the Tesla CEO.

Redfin’s stock soars on buyout deal with Rocket Cos. that looks to speed up home buying